Cargando…
Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: Clinical approach and genetic analysis
Autores principales: | Sinx, Kelly A.E., Roemen, Guido M.J.M., van Zutven, Virrie, Janssen, Renske, Speel, Ernst-Jan M., Steijlen, Peter M., van Geel, Michel, Mosterd, Klara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031482/ https://www.ncbi.nlm.nih.gov/pubmed/29984265 http://dx.doi.org/10.1016/j.jdcr.2017.11.011 |
Ejemplares similares
-
Characterization of intractable diarrhea resulting from vismodegib treatment for basal cell nevus syndrome
por: Patel, Ashmi, et al.
Publicado: (2022) -
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
por: Weiss, Glen J., et al.
Publicado: (2011) -
Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
por: VERKOUTEREN, Babette J. A., et al.
Publicado: (2022) -
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials
por: Chang, Anne Lynn S., et al.
Publicado: (2016) -
Vismodegib: the Proof of Concept in Basal Cell Carcinoma
por: Berrada, Narjiss, et al.
Publicado: (2014)